Southern District of California Court Provides Further Guidance on Patent Infringement Pleading Requirements After Abrogation of Form 18

Nov 30, 2016

Reading Time : 1 min

The court concluded that TSRI failed to meet the pleading standard adopted by the court after the abrogation of Form 18. In its analysis, the court appeared to give substantial weight to the fact that TSRI did not specifically address all of the limitations of the asserted claims in its allegations. The asserted claims are directed to a “bifunctional molecule,” which, according to TSRI, is used to manufacture DNA microarrays. In its complaint, TSRI identified Illumina’s BeadChip as an infringing product and generally described the characteristics of that product. Based on this description, TSRI concluded that the bifunctional molecule used to manufacture the BeadChip product directly infringed its patent. However, TSRI’s allegations did not specifically address all of the limitations in the asserted claims. In particular, as the court emphasized, the defendant identified “several limitations in claim 1 that are not encompassed—much less addressed—by Plaintiff’s allegations.” The court agreed with the defendant that the asserted patent “does not cover just any bifunctional molecule; its claims all require a bifunctional molecule with a specific structure.” The court therefore found that TSRI failed to meet the pleading standard for direct infringement and dismissed TSRI’s direct infringement claims without prejudice.

The Scripps Research Institute v. Illumina, Inc., 16-cv-661 (S.D. Cal. Nov. 21, 2016) (Sammartino, J.)

Share This Insight

Previous Entries

IP Newsflash

December 18, 2025

The Federal Circuit recently vacated a $20 million jury verdict in favor of a patentee and remanded with instructions to dismiss the case for lack of subject matter jurisdiction, finding that the patentee did not own the asserted patents at the time it filed suit and therefore lacked standing.

...

Read More

IP Newsflash

December 17, 2025

The Federal Circuit recently affirmed a Patent Trial and Appeal Board decision finding claims that had been subject to an ex parte reexamination unpatentable. As a threshold issue, the court held that IPR estoppel under 35 USC § 315(e)(1) does not apply to ongoing ex parte reexaminations. Accordingly, the Patent Office did not err in continuing the reexamination after issuing final written decisions in co-pending IPRs.

...

Read More

IP Newsflash

December 15, 2025

The District of Delaware recently denied a defendant’s motion to dismiss plaintiff’s demand for enhanced damages based on willful infringement pursuant to 35 U.S.C. § 284, explaining that neither a demand for damages under § 284 nor an accusation of willful infringement amount to a claim for relief that can be subject to dismissal under Rule 12(b)(6).

...

Read More

IP Newsflash

December 9, 2025

The Federal Circuit recently denied a petition for a writ of mandamus that challenged the PTO Director’s reliance on “settled expectations” to discretionarily deny two inter partes review (IPR) petitions. In so doing, the court explained that, while it was not deciding whether the Director’s use of “settled expectations” was correct, the petitioner’s arguments about what factors the Director may consider when deciding whether to institute an IPR or post-grant review (PGR) are not generally reviewable and did not provide sufficient basis for mandamus review here.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.